Pasireotide is a medication used to treat people with acromegaly or Cushing’s disease, both of which are hormonal disorders caused by a non-cancerous tumor (adenoma) in the pituitary gland. Because of the way pasireotide works to treat these conditions, sometimes blood sugar levels can increase during treatment, causing a side effect known as hyperglycemia. This is a summary about a study called B2219 (ClinicalTrials.gov ID: NCT02060383), which was designed specifically to look at which additional medication(s) work(s) best to reduce blood sugar levels (antihyperglycemic medication) for people who require treatment for hyperglycemia while receiving pasireotideThis Plain Language Summary of Publication article (PLSP) from Future Rare Diseases focusses on a side effect of a medication known as pasireotide. Pasireotide sometimes causes blood sugar levels to increase during treatment, causing a side effect called hyperglycemia. The B2219 study looked at which additional medication works best to reduce this side effect.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study’ and was published in Pituitary. 

Visit the Springer Link site using the link to read the article.